The constant increase in the rate of cutaneous melanoma over recent years and its resistance to anti-tumour pharmaceutical drugs has meant that the study of cutaneous melanoma is one of the greatest scientific challenges in the field of cancer. The Human Melanoma research team at the University of the Basque Country (UPV/EHU) is focusing on this study.

Treatment with anti-tumor necrosis factor (TNF) agents is recognized as a risk factor for tuberculosis (TB) in patients with immune-mediated inflammatory diseases such as rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, psoriatic arthritis and psoriasis. Most TB cases develop as a result of reactivation of a latent TB infection, and health authorities worldwide recommend screening for latent TB and treating patients before initiating anti-TNF treatment.

In-growth and new generation of blood vessels, which must take place if a wound is to heal or a tumor is to grow, have been thought to occur through a branching and further growth of a vessel against a chemical gradient of growth factors. Now a research team at Uppsala University and its University Hospital has shown that mechanical forces are considerably more important than was previously thought.

It has long been known that heat is an effective weapon against tumor cells. However, it's difficult to heat patients' tumors without damaging nearby tissues.

Researchers at the University of North Carolina at Chapel Hill School of Medicine have identified a compound that could be modified to treat one of the most deadly types of cancer, and discovered how a particular gene mutation contributes to tumor growth.

A new multi-center study shows that an experimental drug lowers prostate specific antigen (PSA) levels – a marker for tumor growth – in men with advanced prostate cancer for whom traditional treatment options have failed.

New research published in this month's edition of Obstetrics & Gynecology (Vol. 113, Issue 4), by a team of investigators from The Cancer Institute of New Jersey (CINJ) shows better survival outcomes for women who have cancer of the ovaries and endometrial lining of the uterus at the same time (synchronous) than those who only have one tumor in the ovaries. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.

With a single incision hidden in the navel, surgeons at the University of California, San Diego Medical Center have successfully removed a cancerous kidney tumor while saving the patient's kidney. The surgical team extracted the tumor through the 3.5 centimeter port then completed the complex task of preserving and reconstructing the kidney. UC San Diego Medical Center is the second hospital in the world to perform this procedure.

Cancer researchers led by Bruce Boman, M.D., Ph.D. director of Cancer Genetics and Stem Cell Biology at the Helen F. Graham Cancer Center of the Christiana Care Health System, and a faculty member at the University of Delaware, have discovered an enzyme common to both normal and malignant colon stem cells that will assist scientists searching for a cure for colon cancer.